Proteome Sciences plc
("Proteome Sciences" or the "Company")
Director/PDMR Shareholding
The Company announces that on 21 March 2018 Roger McDowell, a Non-Executive Director of the Company, sold 500,000 ordinary shares of 1 pence each ("Ordinary Shares") at a price of 3 pence per Ordinary Share and bought, into his SIPP, 500,000 Ordinary Shares at a price of 3.006 pence per Ordinary Share (the "Transfer").
Following the Transfer, Mr McDowell's beneficial interest in the Company remains at 2,500,000 Ordinary Shares representing approximately 0.91% of the issued share capital of the Company.
For further information: Proteome Sciences plc |
|
Jeremy Haigh, Chief Executive Officer Tel: +44 (0)20 7043 2116 |
|
Ian Pike, Chief Scientific Officer |
|
Stefan Fuhrman, Finance Director |
|
finnCap Limited (Nominated Adviser/Broker) |
|
Geoff Nash/James Thompson |
Tel: +44 (0)20 7220 0500 |
Tony Quirke (broking) |
|
|
|
About Proteome Sciences plc. (www.proteomics.com):
Proteome Sciences is a leader in applied proteomics offering high sensitivity, proprietary technologies and workflows for mapping cell signalling pathways (SysQuant®) and for the discovery, validation and assay development of protein biomarkers (TMTcalibrator™). The company has its headquarters in London, UK, with laboratory facilities in Frankfurt, Germany from where the PS Biomarker Services™ division provides outsourced proteomics services and proprietary biomarker assays to biopharmaceutical and diagnostics companies and to academia.
Proteome Sciences has patented a number of novel protein biomarkers for diagnostic and treatment applications in important areas of human therapeutics such as cancer, stroke and Alzheimer's disease, and these are available for license.
1. |
Details of the person discharging managerial responsibilities / person closely associated |
|
a) |
Name |
Roger McDowell |
2. |
Reason for the Notification |
|
a) |
Position/status |
Non-Executive Director |
b) |
Initial notification/Amendment |
Initial notification |
3. |
Details of the issuer, emission allowance market participant, auction platform, auctioneer or auction monitor |
|
a) |
Name |
Proteome Sciences plc |
b) |
LEI |
213800Q62ICXANKU2986 |
4. |
Details of the transaction(s): section to be repeated for (i) each type of instrument; (ii) each type of transaction; (iii) each date; and (iv) each place where transactions have been conducted |
|
a) |
Description of the Financial instrument, type of instrument |
Ordinary Shares of 1p each |
Identification code |
GB0003104196 |
|
b) |
Nature of the transaction |
Purchase and sale of shares |
c) |
Price(s) and volume(s) |
500,000 Ordinary Shares bought at 3.006p per Ordinary Share 500,000 Ordinary Shares sold at 3.000p per Ordinary Share
|
d) |
Aggregated information: · Aggregated volume · Price |
500,000 Ordinary Shares bought at 3.006p per Ordinary Share 500,000 Ordinary Shares sold at 3.000p per Ordinary Share
|
e) |
Date of the transaction |
21 March 2018 |
f) |
Place of the transaction |
London Stock Exchange, AIM Market (XLON) |